Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.

Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.

AbbVie follows Gilead in throwing Xilio a lifeline.

Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.

Poor efficacy clouds prospects for the company's "improved" Yervoy.

Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.

Merck ditches vibostolimab and favezelimab following huge pivotal programmes.

Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.

The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.